Recently, our group found that CXCR3‐expressing B cells are abundant in the MS CNS and selectively accumulate in the blood of MS patients treated with natalizumab (NTZ; anti‐VLA‐4 mAb) [10], an effective drug that prevents their infiltration into the CNS. This evidence concerns the gene CXCR3 and myeloid sarcoma.